Cidara Therapeutics Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Cidara Therapeutics

Dividende od Cidara Therapeutics su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Cidara Therapeutics tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Cidara Therapeutics su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Cidara Therapeutics mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Cidara Therapeutics Aktienanalyse

Шта ради Cidara Therapeutics?

Cidara Therapeutics Inc. is a biopharmaceutical company specializing in the development and marketing of innovative therapies for serious infectious diseases. The company was founded in 2013 and is headquartered in San Diego, California. The founders of Cidara Therapeutics Inc. aimed to develop a new class of antifungal drugs that are particularly effective against fungal infections. The underlying technology is based on the Cloudbreak® peptide platform, which allows for the production of drugs with improved efficacy and safety. The company also has research collaborations with leading scientists in the field of infectious diseases to advance the development of antibody therapy, vaccines, and other drugs. The business model of Cidara Therapeutics Inc. focuses on the development and marketing of innovative therapeutic products for unmet medical needs. The company has divided its products into three divisions: infectious diseases, oncology, and immunology. Cidara's product pipeline includes several innovative drugs that have shown efficacy in phase I and phase II clinical trials. The infectious diseases division initially focuses on the development of antifungal drugs for the treatment of Candida infections, which can be life-threatening for people with weakened immune systems. Cidara Therapeutics Inc. has already successfully completed a clinical trial for its lead product, rezafungin. Rezafungin is a long-acting, liposomal antifungal drug that enables a single dose for effective treatment of Candida infections. The oncology division focuses on the development of innovative immunotherapies that use the body's immune system to attack cancer cells. Cidara Therapeutics Inc. utilizes the Cloudbreak® platform technology to develop new drugs that specifically target certain types of cancer. The lead product in this pipeline is CD371, a monoclonal antibody targeting acute myeloid leukemia (AML). The immunology division focuses on developing therapeutics for autoimmune diseases that bring the body's immune system under medical control to reduce inflammation and damage to target organs. The lead product in this product line is Cloudbreak® immunomodulators, which specifically regulate immune responses and combat inflammation. Overall, Cidara Therapeutics Inc. is a promising company that focuses on the development and marketing of innovative drugs for high unmet medical needs. The company's diverse and well-balanced product pipelines in the areas of infectious diseases, oncology, and immunology demonstrate the great potential of this business model. With the advanced Cloudbreak® technology and the dedicated team, Cidara Therapeutics Inc. has the potential to take a global leadership role in drug development and save lives. Cidara Therapeutics je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Cidara Therapeutics akciji

Kolika je dividenda koju isplaćuje Cidara Therapeutics?

U poslednjih 12 meseci, Cidara Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Cidara Therapeutics će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Cidara Therapeutics?

Dividendski prinos od Cidara Therapeutics trenutno iznosi .

Kada Cidara Therapeutics isplaćuje dividendu?

Cidara Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Cidara Therapeutics?

Cidara Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Cidara Therapeutics?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Cidara Therapeutics?

Cidara Therapeutics se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Cidara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Cidara Therapeutics od 8. 6. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 8. 6. 2024..

Kada je Cidara Therapeutics poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 8. 6. 2024..

Kolika je bila dividenda od Cidara Therapeutics u godini 2023?

U godini 2023 kompanija Cidara Therapeutics je isplatila 0 USD kao dividende.

U kojoj valuti Cidara Therapeutics isplaćuje dividendu?

Dividende od Cidara Therapeutics se isplaćuju u USD.